Armored CAR T cells for GPC3-positive solid tumors
Part of Cancer, Digestive system, Genetic & congenital, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new type of immunotherapy called CAR T cells that are trained to find and attack cancer cells with a specific marker (GPC3). The CAR T cells are also 'armored' with extra proteins (IL-15 and IL-21) to help them work better. It might be an option for adults with advanced solid tumors, especially liver cancer, that have not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor must have a protein called GPC3 at a moderate to high level (grade 2 or higher), confirmed by a biopsy.
- You must be 21 years old or older.
- You need to have a performance status score of 60% or higher (meaning you can do most daily activities with some help).
- If you have liver cancer (hepatocellular carcinoma), your liver function score (Child-Pugh) must be less than 7 and your cancer stage must be A, B, or C.
- Your cancer must have continued to grow or come back after at least one standard treatment and one stronger treatment (salvage therapy).
- You cannot have had an organ transplant, HIV, an active infection (except hepatitis B or C), or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a customized immune-cell treatment (CAR T cells) made to recognize GPC3, a marker found on some tumors. It’s designed for children and young people whose solid tumors have not been cured by standard treatment and who can safely receive this therapy.
This trial tests a new type of immune cell (CAR T cell) that targets a protein called GPC3 found on certain solid tumors. It aims to see if these cells are safe and can help adults with liver cancer or other GPC3-positive tumors that have not responded to standard treatments.
This trial tests a new kind of immunotherapy for children and teens with solid tumors that have not responded to standard treatments. The therapy uses specially engineered T cells (CAR T cells) that target a protein called GPC3 found on many tumor cells, and it includes extra signals (IL-15 and IL-21) to help the T cells work better.
This trial tests a custom immune-cell treatment (CAR-T) that targets a marker called GPC3 in people with advanced hepatocellular carcinoma (a type of liver cancer). It’s for cases where standard treatments have not worked well, and the goal is to shrink tumors and improve outcomes.
This early-phase trial tests a personalized CAR-T cell treatment for cancers that make a lot of a protein called GPC3. If you have advanced cancer that has already tried at least one standard treatment, and your tumor has enough GPC3, this study aims to see how well the treatment can shrink tumors and how safe it is.
This Phase 1 study tests a personalized immune-cell treatment (CAR T cells) for advanced liver cancer that has the GPC3 protein. It aims to see whether these engineered cells can find and kill cancer cells safely and help shrink the cancer.
Hear when a new Hepatoblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.